Antimicrobial Resistant Organisms (ARO) Surveillance SURVEILLANCE REPORT FOR DATA FROM JANUARY TO DECEMBER
|
|
- Hubert Fields
- 6 years ago
- Views:
Transcription
1 Antimicrobial Resistant Organisms (ARO) Surveillance SURVEILLANCE REPORT FOR DATA FROM JANUARY TO DECEMBER
2 TO PROMOTE AND PROTECT THE HEALTH OF CANADIANS THROUGH LEADERSHIP, PARTNERSHIP, INNOVATION AND ACTION IN PUBLIC HEALTH. Également disponible en français sous le titre : Surveillance des micro-organismes résistants aux antimicrobiens: Rapport de surveillance sur les résultats du 1 janvier 2007 au 31 décembre 2011 This publication can be made available in alternative formats upon request. Her Majesty the Queen in Right of Canada, as represented by the Minister of Health, 2013 Publication date: November, 2013 Cat.: HP5-116/2013E-PDF ISBN: Pub.: Updated September 2013
3 Antimicrobial Resistant Organisms (ARO) Surveillance SURVEILLANCE REPORT FOR DATA FROM JANUARY TO DECEMBER Updated September 2013
4 1 Antimicrobial Resistant Organisms (ARO) Surveillance Introduction The (The Agency) collects national data on antimicrobial resistant organisms (AROs) through the Canadian Nosocomial infection Surveillance Program (CNISP), a collaborative effort of the Centre for Communicable Diseases and Infection Control (CCDIC), the National Microbiology Laboratory (NML) and sentinel hospitals across Canada who participate as members of the Canadian Hospital Epidemiology Committee (a subcommittee of the Association of Medical Microbiology and Infectious Disease Canada). CNISP surveillance provides key information that informs the development of federal and provincial infection prevention and control programs and policies and provides rates and trends on antimicrobial resistant organisms. In addition, if carried out in a uniform manner, surveillance provides a measure of the burden of illness, establishes benchmark rates for internal and external comparison, identifies potential risk factors, and allows assessment of specific interventions. Surveillance for AMR is considered an important measure of the quality of patient care. The enclosed ARO tables are intended to provide up to date/timely CNISP rates to the provincial and territorial health authorities. The results are subject to change as new data is made available by the participating hospitals. The rates include Clostridium difficile Infection (CDI), Methicillin-Resistant Staphylococcus aureus (MRSA), Vancomycin-Resistant Enterococci (VRE) and Carbapenem-Producing Enterobacteriaceae (CPO). Case definitions and eligibility criteria for CNISP ARO surveillance are provided in Appendix A. Interpretation and discussion of the results can be found in the Agency fact sheets and surveillance reports. The surveillance reports are published every two years. At present, CNISP conducts surveillance in 57 largely, university-affiliated tertiary care hospitals (i.e. major hospitals that offer a range of specialist services) from 10 provinces. When possible, rates are provided by the type of facility (adult, adult/mixed and pediatric) and the region such as Western (British Columbia, Alberta, Saskatchewan and Manitoba), Central (Ontario and Quebec), and Eastern (Nova Scotia, New Brunswick, Prince Edward Island and Newfoundland and Labrador). The territories do not currently submit data to the Agency and Prince Edward Island only began submitting data in The list of participating CNISP hospitals and their corresponding CHEC members is provided in Appendix B. The publication of this report would not be possible without the submission of ARO data from all participating hospitals listed in Appendix B. Their ongoing contributions to national ARO surveillance are gratefully acknowledged. For questions or more information on these rates or for a copy of the most recent Agency surveillance report, please contact the Centre for Communicable Disease and Infection Control, by sending an to ccdic-clmti@phac-aspc.gc.ca
5 2 Antimicrobial Resistant Organisms (ARO) Surveillance 1. Healthcare-Associated-Clostridium difficile Infection (HA-CDI) Table 1 Number of Healthcare-Associated-Clostridium difficile infection cases and incidence rates per 1,000 patient admissions by region , , , , , , , , , , , , , , Table 2 Number of Healthcare-Associated-Clostridium difficile infection cases and incidence rate per 10,000 patient days by region Rate per 10,000 patient days , , , , , , , , , , , , , ,
6 3 Antimicrobial Resistant Organisms (ARO) Surveillance Table 3 Number of Healthcare-Associated-Clostridium difficile infection cases and incidence rates per 1,000 patient admissions by type of facility Type of Facility Adult and mixed Pediatric stand-alone Overall No.cases Rate No.cases Rate No.cases Rate , , , , , , , , , , Adult and mixed are comprised of hospitals that provide services to both adult and pediatric patients. Typically, the pediatric patients represent less than 10% of the hospital population. Table 4 Number of Healthcare-Associated-Clostridium difficile infection cases and incidence rate per 10,000 patient days by type of facility Rate per 10,000 patient days Type of Facility Adult and mixed Pediatric stand-alone Overall No.cases Rate No.cases Rate No.cases Rate , , , , , , , , , , Adult and mixed are comprised of hospitals that provide services to both adult and pediatric patients. Typically, the pediatric patients represent less than 10% of the hospital population. Table 5 Attributable mortality rate 30 days after date of positive culture per 100 HA-CDI cases Number of death* Mortality rate per 100 HA-CDI cases *Deaths directly and indirectly related to HA-CDI 30 days after onset of HA-CDI
7 4 Antimicrobial Resistant Organisms (ARO) Surveillance 7.00 CNISP HA-CDI per 1,000 patient admissions West Central East Overall CNISP HA-CDI per 10,000 patient days West Central East Overall
8 5 Antimicrobial Resistant Organisms (ARO) Surveillance 2. Methicillin-Resistant Staphylococcus aureus (MRSA) Table 1 Number of Methicillin-Resistant Staphylococcus aureus rate (infection and colonization) cases and incidence rate per 1,000 admissions by region , , , , , , , , , , , , Table 2 Number of Methicillin-Resistant Staphylococcus aureus rate (infection and colonization) cases and incidence rate per 10,000 patient days by region Rate per 10,000 patient days , , , , , , , , , , , ,
9 6 Antimicrobial Resistant Organisms (ARO) Surveillance Table 3 Number of Methicillin-Resistant Staphylococcus aureus rate (infection and colonization) cases and incidence rate per 1,000 patient admissions by type of facility Adult stand-alone Pediatric stand-alone Type of Facility Adult and mixed Overall , , , , , , , , , , , , Adult and mixed are comprised of hospitals that provide services to both adult and pediatric patients. Typically, the pediatric patients represent less than 10% of the hospital population. Table 4 Number of Methicillin-Resistant Staphylococcus aureus rate (infection and colonization) cases and incidence rate per 10,000 patient days by type of facility Adult stand-alone Rate per 10,000 patient days Pediatric stand-alone Type of Facility Adult and mixed Overall , , , , , , , , , , , , Adult and mixed are comprised of hospitals that provide services to both adult and pediatric patients. Typically, the pediatric patients represent less than 10% of the hospital population.
10 7 Antimicrobial Resistant Organisms (ARO) Surveillance Table 5 Methicillin-Resistant Staphylococcus aureus infection rate per 1,000 patient admissions by region , , , , , Table 6 Methicillin-Resistant Staphylococcus aureus infection rate per 10,000 patient days by region Rate per 10,000 patient days , , , , ,
11 8 Antimicrobial Resistant Organisms (ARO) Surveillance Table 7 Methicillin-Resistant Staphylococcus aureus infection rate per 1,000 patient admissions by type of facility Adult stand-alone Pediatric stand-alone Type of Facility Adult and mixed Overall , , , , , , , , Adult and mixed are comprised of hospitals that provide services to both adult and pediatric patients. Typically, the pediatric patients represent less than 10% of the hospital population. Table 8 Methicillin-Resistant Staphylococcus aureus infection rate per 10,000 patient days by type of facility Adult stand-alone Rate per 10,000 patient days Pediatric stand-alone Type of Facility Adult and mixed Overall , , , , , , , , Adult and mixed are comprised of hospitals that provide services to both adult and pediatric patients. Typically, the pediatric patients represent less than 10% of the hospital population.
12 9 Antimicrobial Resistant Organisms (ARO) Surveillance CNISP MRSA infections per 1,000 patient admissions West Central East Overall CNISP MRSA infections per 10,000 patient days West Central East Overall
13 10 Antimicrobial Resistant Organisms (ARO) Surveillance Table 9 Healthcare-Associated* Methicillin-resistant Staphylococcus aureus infection rate per 1,000 patient admissions by region , , , , *HA-MRSA includes all cases identified within the CNISP hospital and any other healthcare setting (clinics, LTC) Table 10 Healthcare-Associated* Methicillin-resistant Staphylococcus aureus infection rate per 10,000 patient days by region Rate per 10,000 patient days , , , , *HA-MRSA includes all cases identified within the CNISP hospital and any other healthcare setting (clinics, LTC)
14 11 Antimicrobial Resistant Organisms (ARO) Surveillance Table 11 Healthcare-Associated* Methicillin-resistant Staphylococcus aureus (HA-MRSA) infection rate per 1,000 patient admissions by type of facility Adult stand-alone Pediatric stand-alone Type of Facility Adult and mixed Overall , , , , , , Adult and mixed are comprised of hospitals that provide services to both adult and pediatric patients. Typically, the pediatric patients represent less than 10% of the hospital population. *HA-MRSA includes all cases identified within the CNISP hospital and any other healthcare setting (clinics, LTC) Table 12 Healthcare-Associated* Methicillin-resistant Staphylococcus aureus (HA-MRSA) infection rate per 10,000 patient days by type of facility Adult stand-alone Rate per 10,000 patient days Pediatric stand-alone Type of Facility Adult and mixed Overall , , , , , , Adult and mixed are comprised of hospitals that provide services to both adult and pediatric patients. Typically, the pediatric patients represent less than 10% of the hospital population. *HA-MRSA includes all cases identified within the CNISP hospital and any other healthcare setting (clinics, LTC)
15 12 Antimicrobial Resistant Organisms (ARO) Surveillance 3.50 CNISP HA-MRSA infections per 1,000 patient admissions West Central East Overall CNISP HA-MRSA infections per 10,000 patient days West Central East Overall
16 13 Antimicrobial Resistant Organisms (ARO) Surveillance Table 13 Community-Associated Methicillin-resistant Staphylococcus aureus (CA-MRSA) infection rate per 1,000 patient admissions by region Table 14 Community-Associated Methicillin-resistant Staphylococcus aureus (CA-MRSA) infection rate per 10,000 patient days by region Rate per 10,000 patient days
17 14 Antimicrobial Resistant Organisms (ARO) Surveillance Table 15 Community-Associated Methicillin-resistant Staphylococcus aureus (CA-MRSA) infection rate per 1,000 patient admissions by type of facility Adult stand-alone Pediatric stand-alone Type of Facility Adult and mixed Overall Adult and mixed are comprised of hospitals that provide services to both adult and pediatric patients. Typically, the pediatric patients represent less than 10% of the hospital population. Table 16 Community-Associated Methicillin-resistant Staphylococcus aureus (CA-MRSA) infection rate per 10,000 patient days by type of facility Adult stand-alone Rate per 10,000 patient days Pediatric stand-alone Type of Facility Adult and mixed Overall Adult and mixed are comprised of hospitals that provide services to both adult and pediatric patients. Typically, the pediatric patients represent less than 10% of the hospital population.
18 15 Antimicrobial Resistant Organisms (ARO) Surveillance 1.20 CNISP CA-MRSA infections per 1,000 patient admissions West Central East Overall CNISP CA-MRSA infections per 10,000 patient days West Central East Overall
19 16 Antimicrobial Resistant Organisms (ARO) Surveillance Table 17 Methicillin-resistant Staphylococcus aureus bloodstream (MRSA-BSI) infection rate per 1,000 patient admissions by region Table 18 Methicillin-resistant Staphylococcus aureus bloodstream (MRSA-BSI) infection rate per 10,000 patient days by region Rate per 10,000 patient days *Number of MRSA BSI cases used in rates may be < than total number of MRSA BSI as only those hospitals that provided both numerator and denominator data were used in calculation of rates Table 19 All-cause mortality rate 30 days after date of positive culture per 100 MRSA-BSI cases Number of deaths All-cause mortality rate per 100 MRSA-BSI cases
20 17 Antimicrobial Resistant Organisms (ARO) Surveillance 0.80 CNISP MRSA-BSI infections per 1,000 patient admissions West Central East Overall CNISP MRSA-BSI infections per 10,000 patient admissions West Central East Overall
21 18 Antimicrobial Resistant Organisms (ARO) Surveillance 3. Vancomycin-Resistant Enterococci (VRE) Table 1 Vancomycin-Resistant Enterococci infection rates per 1,000 patient admissions by region Table 2 Vancomycin-Resistant Enterococci infection rates per 1,000 patient admissions by facility type Type of Facility Adult and mixed Pediatric stand-alone Overall No.cases Rate No.cases Rate No.cases Rate Adult and mixed are comprised of hospitals that provide services to both adult and pediatric patients. Typically, the pediatric patients represent less than 10% of the hospital population.
22 19 Antimicrobial Resistant Organisms (ARO) Surveillance Table 3 Vancomycin-Resistant Enterococci infection rates per 10,000 patient days by region Rate per 10,000 patient-days Table 4 Vancomycin-Resistant Enterococci infection rates per 10,000 patient days by facility type Rate per 10,000 patient-days Type of Facility Adult and mixed Pediatric stand-alone Overall No.cases Rate No.cases Rate No.cases Rate Adult and mixed are comprised of hospitals that provide services to both adult and pediatric patients. Typically, the pediatric patients represent less than 10% of the hospital population.
23 20 Antimicrobial Resistant Organisms (ARO) Surveillance CNISP VRE infections per 1,000 patient admissions West Central East Overall CNISP VRE infections per 10,000 patient days West Central East Overall
24 21 Antimicrobial Resistant Organisms (ARO) Surveillance Table 5 Vancomycin-Resistant Enterococci colonization rates per 1,000 patient admissions by region , , , , , , , , , , , , , Table 6 Vancomycin-Resistant Enterococci colonization rates per 1,000 patient admissions by facility type Type of Facility Adult and mixed Pediatric stand-alone Overall No.cases Rate No.cases Rate No.cases Rate , , , , , , , , , , Adult and mixed are comprised of hospitals that provide services to both adult and pediatric patients. Typically, the pediatric patients represent less than 10% of the hospital population.
25 22 Antimicrobial Resistant Organisms (ARO) Surveillance Table 7 Vancomycin-Resistant Enterococci colonization rates per 10,000 patient days by region Rate per 10,000 patient-days Table 8 Vancomycin-Resistant Enterococci colonization rates per 10,000 patient days by facility type Rate per 10,000 patient-days Type of Facility Adult and mixed Pediatric stand-alone Overall No.cases Rate No.cases Rate No.cases Rate Adult and mixed are comprised of hospitals that provide services to both adult and pediatric patients. Typically, the pediatric patients represent less than 10% of the hospital population.
26 23 Antimicrobial Resistant Organisms (ARO) Surveillance Table 9 Healthcare-associated Vancomycin-Resistant Enterococci infection rates per 1,000 patient admissions by region for the reporting CNISP hospitals* *site of acquisition was no longer collected after 2010 Note: data on community acquired (CA) VRE infections is not included as only 15 CA-VRE infections were reported from 2006 to Table 10 Healthcare-associated Vancomycin-Resistant Enterococci infection rates per 10,000 patient-days by region for the reporting CNISP hospitals* Rate per 10,000 patient days *site of acquisition was no longer collected after 2010 Note: data on community acquired (CA) VRE infections is not included as only 15 CA-VRE infections were reported from 2006 to 2010.
27 24 Antimicrobial Resistant Organisms (ARO) Surveillance Table 11 Healthcare-associated Vancomycin-Resistant Enterococci colonization rates per 1,000 patient admissions by region for the reporting CNISP hospitals* , , , , , , , , *site of acquisition was no longer collected after 2010 Table 12 Healthcare-associated Vancomycin-Resistant Enterococci colonization rates per 10,000 patient-days by region for the reporting CNISP hospitals* Rate per 10,000 patient days , , , , , , , , *site of acquisition was no longer collected after 2010
28 25 Antimicrobial Resistant Organisms (ARO) Surveillance 4. Carbapenemase-Producing Organisms (CPO) Table 1 Number of cases of Carbapenemase-Producing Organisms (CPO) by region Number of cases* Total *Rates are pending awaiting final denominator data Table 2 All-cause and attributable mortality rate 30 days after date of positive culture per 100 CPO cases Number of deaths All-cause mortality rate per 100 CPO cases Number of attributable deaths* Attributable mortality rate per 100 CPO cases* % 1 2.4% % % 2 3.7% Total % 3 1.9% *CPO was the primary or contributing cause of death 30 days after diagnosis
ANTIMICROBIAL RESISTANT ORGANISMS (ARO) SURVEILLANCE
Antimicrobial Resistant Organisms (ARO) Surveillance ANTIMICROBIAL RESISTANT ORGANISMS (ARO) SURVEILLANCE SUMMARY REPORT FOR DATA FROM JANUARY 1, 2009 TO DECEMBER 31, 2013 Updated October 2014 Antimicrobial
More informationHEALTHCARE- ASSOCIATED CLOSTRIDIUM DIFFICILE INFECTIONS IN CANADIAN ACUTE- CARE HOSPITALS
HEALTHCARE- ASSOCIATED CLOSTRIDIUM DIFFICILE INFECTIONS IN CANADIAN ACUTE- CARE HOSPITALS SURVEILLANCE REPORT JANUARY 1 st, 2007 TO DECEMBER 31 st, 2012 TO PROMOTE AND PROTECT THE HEALTH OF CANADIANS THROUGH
More informationReport from the National Diabetes Surveillance System:
Report from the National Diabetes Surveillance System: Diabetes in Canada, 28 To promote and protect the health of Canadians through leadership, partnership, innovation and action in public health. Public
More informationTUBERCULOSIS IN CANADA 2010 PRE-RELEASE
TUBERCULOSIS IN CANADA 2010 PRE-RELEASE Our mission is to promote and protect the health of Canadians through leadership, partnership, innovation and action in public health. - Public Health Agency of
More informationPhysiotherapists in Canada, 2011 National and Jurisdictional Highlights
pic pic pic Physiotherapists in Canada, 2011 National and Jurisdictional Highlights Spending and Health Workforce Our Vision Better data. Better decisions. Healthier Canadians. Our Mandate To lead the
More informationAussi disponible en français sous le titre : Le Diabète au Canada : Rapport du Système national de surveillance du diabète, 2009
Report from the National Diabetes Surveillance System: Diabetes in Canada, 29 To promote and protect the health of Canadians through leadership, partnership, innovation and action in public health. Public
More informationYOUR SEASONAL FLU GUIDE
YOUR SEASONAL FLU GUIDE b What is the seasonal flu? b What can you do to prevent the seasonal flu? b Resources WWW.FIGHTFLU.CA To promote and protect the health of Canadians through leadership, partnership,
More informationVACCINE COVERAGE IN CANADIAN CHILDREN
VACCINE COVERAGE IN CANADIAN CHILDREN RESULTS FROM THE 2013 CHILDHOOD NATIONAL IMMUNIZATION COVERAGE SURVEY (CNICS) REVISED EDITION FEBRUARY 2017 PROTECTING AND EMPOWERING CANADIANS TO IMPROVE THEIR HEALTH
More informationNovember 5 to 11, 2017 (Week 45)
Hanks you Overall Summary November 5 to 11, 2017 (Week 45) Influenza activity crossed the seasonal threshold in week 45, indicating the beginning of the influenza season at the national level. The number
More informationProvincial Projections of Arthritis or Rheumatism, Special Report to the Canadian Rheumatology Association
ARTHRITIS COMMUNITY RESEARCH & EVALUATION UNIT (ACREU) The Arthritis and Immune Disorder Research Centre Health Care Research Division University Health Network February, 2000 Provincial Projections of
More informationDecember 3 to 9, 2017 (Week 49)
Hanks you December 3 to 9, 2017 (Week 49) Overall Summary Overall, Influenza activity continues to increase across Canada; however many indicators such as hospitalizations, outbreaks and geographic spread
More informationWest Nile virus and Other Mosquito borne Diseases National Surveillance Report English Edition
and Other Mosquito borne Diseases National Surveillance Report English Edition July to July 8, 17 (Week 7) West Nile Virus Canada Humans As of surveillance week 7, ending on July 8, 17, the Public Health
More informationREPORT FROM THE CANADIAN CHRONIC DISEASE SURVEILLANCE SYSTEM:
REPORT FROM THE CANADIAN CHRONIC DISEASE SURVEILLANCE SYSTEM: PROTECTING AND EMPOWERING CANADIANS TO IMPROVE THEIR HEALTH TO PROMOTE AND PROTECT THE HEALTH OF CANADIANS THROUGH LEADERSHIP, PARTNERSHIP,
More informationLessons learned from building IPAC surveillance
IPAC-Canada Conference Banff 2018 Pearls of Wisdom Lessons learned from building IPAC surveillance Objectives to describe Context of total network surveillance Components of sustainable surveillance systems
More information2018 CNISP HAI Surveillance Case definitions
2018 CNISP HAI Surveillance Case definitions The following case definitions for the surveillance of healthcare-associated infections (HAIs) are used by all acute-care hospitals that participate in the
More informationREPORT ON SEXUALLY TRANSMITTED INFECTIONS IN CANADA: 2012
REPORT ON SEXUALLY TRANSMITTED INFECTIONS IN CANADA: 2012 CENTRE FOR COMMUNICABLE DISEASES AND INFECTION CONTROL PUBLIC HEALTH AGENCY OF CANADA PROTECTING CANADIANS FROM ILLNESS TO PROMOTE AND PROTECT
More informationCOMMUNICABLE DISEASE REPORT
COMMUNICABLE DISEASE REPORT Quarterly Report Volume 30, Number 3 December 2013 Healthcare-associated Infections In this quarter, healthcare-associated infections will be highlighted with an overview of
More informationCHAPTER 4: Population-level interventions
CHAPTER 4: Population-level interventions Population-level interventions refer to policies and programs that are applied to entire populations to promote better health outcomes. In this chapter, we describe
More informationAntimicrobial Resistance Surveillance Data Requirements for Priority Organisms
Antimicrobial Resistance Surveillance Data Requirements for Priority Organisms The Communicable and Infectious Disease Steering Committee Antimicrobial Resistance Surveillance Task Group Final Report to
More informationOxyContin in the 90 days prior to it being discontinued.
Appendix 1 (as supplied by the authors): Supplementary data Provincial Drug Insurance program formulary listing status for OxyNeo by province Province Listing of OxyNeo BC Listed for patients covered by
More informationTRANSFUSION TRANSMITTED INJURIES SURVEILLANCE SYSTEM (TTISS): SUMMARY RESULTS. 1 P age
TRANSFUSION TRANSMITTED INJURIES SURVEILLANCE SYSTEM (TTISS): 2009-2013 SUMMARY RESULTS 1 P age Acknowledgments: The development of the Transfusion Transmitted Surveillance System (TTISS) would not have
More informationREPORT FROM THE CANADIAN CHRONIC DISEASE SURVEILLANCE SYSTEM: ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN CANADA, 2018
REPORT FROM THE CANADIAN CHRONIC DISEASE SURVEILLANCE SYSTEM: ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN CANADA, 2018 P R O T E C T I N G A N D E M P O W E R I N G C A N A D I A N S T O
More informationTuberculosis. Drug resistance in Canada. Reported susceptibility results of the Canadian Tuberculosis Laboratory Surveillance System
Public Health Agency of Canada Agence de la santé publique du Canada Tuberculosis Drug resistance in Canada Reported susceptibility results of the Canadian Tuberculosis Laboratory Surveillance System Our
More informationTRANSFUSION ERROR SURVEILLANCE SYSTEM (TESS) Report
TRANSFUSION ERROR SURVEILLANCE SYSTEM (TESS) 2012-2013 Report TO PROMOTE AND PROTECT THE HEALTH OF CANADIANS THROUGH LEADERSHIP, PARTNERSHIP, INNOVATION AND ACTION IN PUBLIC HEALTH. Public Health Agency
More informationREPORT ON THE ENHANCED SURVEILLANCE OF ANTIMICROBIAL-RESISTANT GONORRHEA
i Report on the enhanced surveillance of antimicrobial-resistant gonorrhea REPORT ON THE ENHANCED SURVEILLANCE OF ANTIMICROBIAL-RESISTANT GONORRHEA RESULTS FROM THE 2014 PILOT i TO PROMOTE AND PROTECT
More informationHealth Interventions in Ambulatory Cancer Care Centres DRAFT. Objectives. Methods
ENVIRONMENTAL SCAN Health Interventions in Ambulatory Cancer Care Centres Context Cancer, a complex, chronic condition, will affect an estimated two in five Canadians in their lifetime. 1 Cancer requires
More informationEstimating the volume of Contraband Sales of Tobacco in Canada
The Canadian Tobacco Market Place Estimating the volume of Contraband Sales of Tobacco in Canada Updated April 2010 Physicians for a Smoke-Free Canada 1226 A Wellington Street Ottawa, Ontario, K1Y 3A1
More informationNational Surveillance of Antimicrobial Susceptibilities of Neisseria gonorrhoeae Annual Summary 2014
1 National Surveillance of Antimicrobial Susceptibilities of Neisseria gonorrhoeae Annual Summary 2012 National Surveillance of Antimicrobial Susceptibilities of Neisseria gonorrhoeae Annual Summary 2014
More informationCritical Care Medicine. Critical Care Medicine Profile
Updated March 2018 Click on any of the contents below to navigate to the slide. Please click the home icon located at the top right of each slide to return to the table of contents slide. TABLE OF CONTENTS
More informationAppendix B Fracture incidence and costs by province
1 Appendix B Fracture incidence and costs by province Comprehensive, accurate fracture numbers and costs are very important data that could help with prioritization and allocation of health care resources.
More informationIndicator Definition
Hospital Acquired Clostridium difficile Infection (CDI) Rate Full data definition sign-off completed. Name of Measure Name of Measure (short) Domain Type of Measure Business Context Rationale Hospital
More informationWe are here to help Provincial offices The Alzheimer Society works Alzheimer Society B.C. right across Canada
Programs & services Who we are Active in communities across Canada, the Alzheimer Society provides information, support and education to people living with Alzheimer s disease and other dementias. We are
More informationImplementing Rapid Response Teams (RRT) National Call September 13, 2007
Implementing Rapid Response Teams (RRT) National Call September 13, 2007 Purpose By the end of this call, participants will have: Heard successes and learnings from Improvement Teams Updated information
More informationWe are here to help Provincial offices The Alzheimer Society works Alzheimer Society B.C. right across Canada
Programs & services Who we are Active in communities across Canada, the Alzheimer Society provides information, support and education to people living with Alzheimer s disease and other dementias. We are
More informationHIV/AIDS Epi Update Public Health Agency of Canada
1 HIV/AIDS Epi Update Public Health Agency of Canada www.phac-aspc.gc.ca/hast-vsmt/ JULY 21 National HIV Prevalence and Incidence Estimates in Canada for 28 At a Glance More Canadians are living with HIV
More informationNovember 9 to 15, 2014 (week 46)
Hanks you November 9 to 15, 2014 (week 46) Overall Summary In week 46, overall influenza activity increased from the previous week with sporadic activity reported in six provinces and one territory. Low-level
More informationAddiction Treatment in Canada: The National Treatment Indicators Report
www.ccsa.ca www.ccdus.ca Addiction Treatment in Canada: The National Treatment Indicators Report 2014 2015 Data December 2017 Addiction Treatment in Canada: The National Treatment Indicators Report 2014
More informationHealth Canada. Santé Canada. Tuberculosis in Canada pre-release
Health Canada Santé Canada Tuberculosis in Canada 2002 pre-release Our mission is to help the people of Canada maintain and improve their health. Health Canada HOW TO REACH US For more information, copies
More informationColorectal Cancer Screening in Canada MONITORING & EVALUATION OF QUALITY INDICATORS RESULTS REPORT
Colorectal Cancer Screening in Canada MONITORING & EVALUATION OF QUALITY INDICATORS RESULTS REPORT JANUARY 2011 DECEMBER 2012 Acknowledgments The Canadian Partnership Against Cancer would like to gratefully
More information12 to 18 January, 2014 (Week 03)
Hanks you 12 to 18 January, 2014 (Week 03) Overall Summary In week 03, overall laboratory detections of influenza decreased slightly, reflecting decreased activity in some regions that experienced an earlier
More information31/08/2017. Point Prevalence Survey for Antimicrobial Resistant Organisms in Canadian Long- Term Facilities. Overview
Point Prevalence Survey for Antimicrobial Resistant Organisms in Canadian Long- Term Facilities IPAC Canada 2017 National Education Conference June 20, 2017 Denise Gravel and the PHAC-IPAC Canada LTC Working
More informationMexico. Figure 1: Confirmed cases of A[H1N1] by date of onset of symptoms; Mexico, 11/07/2009 (Source: MoH)
Department of International & Tropical diseases In order to avoid duplication and to make already verified information available to a larger audience, this document has been adapted from an earlier version
More informationCOLLABORATIVE STAGE TRAINING IN CANADA
COLLABORATIVE STAGE TRAINING IN CANADA CANADIAN COUNCIL OF CANCER REGISTRIES DATA AND QUALITY MANAGEMENT COMMITTEE PRESENTATION NAACCR CONFERENCE JUNE 14, 2006 Regina, Saskatchewan Canada Ingrid Friesen
More informationDEMENTIA IN CANADA, INCLUDING ALZHEIMER S DISEASE
DEMENTIA IN CANADA, INCLUDING ALZHEIMER S DISEASE HIGHLIGHTS FROM THE CANADIAN CHRONIC DISEASE SURVEILLANCE SYSTEM According to the World Health Organization, 47.5 million people live with dementia, including
More informationMental Health Statistics, to
, 1982-83 to 1993-94 Jean Randhawa and Rod Riley* Since the early 1980s, in relation to the size of the population, general and psychiatric hospitals have seen a drop in separations for mental disorders.
More informationCOMMUNICABLE DISEASE REPORT Quarterly Report
COMMUNICABLE DISEASE REPORT Quarterly Report Volume 31, Number 3 December 2014 Healthcare-Associated Infections In past issues of the Communicable Disease Report the focus has been on antibiotic-resistant
More informationEconomic Burden of Musculoskeletal Diseases in Canada
Economic Burden of Musculoskeletal Diseases in Canada Presented by Sylvie Desjardins, Policy Research Unit, Public Health Agency of Canada October 23 rd, 2006 1 Fact Sheet MSK has the higher prevalence
More informationDemand for Ocular Tissue in Canada - Final Report
Demand for Ocular Tissue in Canada - Final Report January 2010 Table of Contents Executive Summary... 3 Background... 4 Purpose... 4 Overview... 4 Limitations... 4 Waiting Lists for Cornea Transplants...
More informationWest Nile Virus and Other Mosquito-borne Diseases National Surveillance Report English Edition September 11 to September 17, 2016 (Week 37)
West Nile Virus and Other Mosquito-borne Diseases National Surveillance Report English Edition September 11 to September 17, 16 (Week 37) Canada Humans During surveillance week 37, ending on September
More informationTuberculosis. Drug resistance in Canada. Reported susceptibility results of the Canadian Tuberculosis Laboratory Surveillance System
Public Health Agency of Canada Agence de la santé publique du Canada Tuberculosis Drug resistance in Canada Reported susceptibility results of the Canadian Tuberculosis Laboratory Surveillance System Our
More informationVACCINE COVERAGE IN CANADIAN CHILDREN
VACCINE COVERAGE IN CANADIAN CHILDREN RESULTS FROM THE 2015 CHILDHOOD NATIONAL IMMUNIZATION COVERAGE SURVEY (cnics) PROTECTING AND EMPOWERING CANADIANS TO IMPROVE THEIR HEALTH TO PROMOTE AND PROTECT THE
More informationCanadian Addiction Survey (CAS)
Canadian Addiction Survey (CAS) A national survey of Canadians use of alcohol and other drugs Prevalence of Use and Related Harms November 2004 HIGHLIGHTS This document was published by the Canadian Centre
More informationHealth Interventions in Ambulatory Cancer Care Centres
ENVIRONMENTAL SCAN Health Interventions in Ambulatory Cancer Care Centres Context Cancer a complex, chronic condition will affect an estimated two in five Canadians in their lifetime. 1 Cancer requires
More informationW H A T N A C D O E S
WHAT IS NAC? Long-standing efforts to improve the status of Canadian women gathered new momentum in 1966 when a small committee led by Laura Sabia, then president of the Canadian Federation of University
More informationNational Treatment Indicators Report
www.ccsa.ca www.cclt.ca National Treatment Indicators Report 21 211 Data March 26, 213 National Treatment Indicators Report 21 211 Data March 26, 213 This document was published by the Canadian Centre
More informationHealth Canada Endorsed Important Safety Information on Infanrix Hexa
Health Canada Endorsed Important Safety Information on Infanrix Hexa October 30, 2012 Dear Health Care Professional: Subject: Voluntary recall of GlaxoSmithKline (GSK) Infanrix Hexa Vaccine Lot A21CB242A
More informationAppendix B: Provincial Case Definitions for Reportable Diseases
Ministry of Health and Long-Term Care Infectious Diseases Protocol Appendix B: Provincial Case Definitions for Reportable Diseases Disease: Carbapenemase-producing Enterobacteriaceae (CPE) infection or
More informationICD-10 Reciprocal Billing File Technical Specifications Reference Guide for Ontario Hospitals
ICD-10 Reciprocal Billing File Technical Specifications Reference Guide for Ontario Hospitals Ministry of Health and Long-Term Care Version 3 January 2014 ICD Reciprocal Billing File Technical Specifications
More informationWest Nile virus and Other Mosquito-borne Diseases National Surveillance Report July 30 to August 5, 2017 (Week 31)
West Nile Virus West Nile virus and Other Mosquito-borne Diseases National Surveillance Report July 3 to August 5, 217 (Week 31) Canada Humans During week 31, July 3 to August 5, 217, the Public Health
More informationAchievements
Celebrating our Achievements 1999-2014 Executive summary www.canadianstrokenetwork.ca Celebrating our Achievements Canadian Stroke Network 1999-2014 Our mission was to reduce the impact of stroke on Canadians
More informationApril 8 to April 14, 2012 (Week 15)
Hanks you April 8 to April 14, 212 (Week 15) Overall Influenza Summary The peak of activity for the 211-212 influenza season in Canada has passed as most indicators of influenza activity continue to decline.
More informationGeneral Internal Medicine. General Internal Medicine Profile
Updated March 2018 1 Click on any of the contents below to navigate to the slide. Please click the home icon located at the top right of each slide to return to the table of contents slide. TABLE OF CONTENTS
More informationWest Nile Virus and Other Mosquito-borne Diseases National Surveillance Report English Edition September 18 to September 24, 2016 (Week 38)
West Nile Virus and Other Mosquito-borne Diseases National Surveillance Report English Edition September 18 to September 4, 16 (Week 38) Canada Humans During surveillance week 38, ending on September 4,
More informationGeriatric Medicine. Geriatric Medicine Profile
Updated August 2018 Click on any of the contents below to navigate to the slide. Please click the home icon located at the top right of each slide to return to the table of contents slide. TABLE OF CONTENTS
More informationAUTISM SPECTRUM DISORDER AMONG CHILDREN AND YOUTH IN CANADA 2018
AUTISM SPECTRUM DISORDER AMONG CHILDREN AND YOUTH IN CANADA 2018 A REPORT OF THE NATIONAL AUTISM SPECTRUM DISORDER SURVEILLANCE SYSTEM PROTECTING AND EMPOWERING CANADIANS TO IMPROVE THEIR HEALTH TO PROMOTE
More informationHuman Papillomavirus (HPV) Vaccination Program Update
STAFF REPORT ACTION REQUIRED Human Papillomavirus (HPV) Vaccination Program Update Date: September 4, 2008 To: From: Wards: Board of Health Medical Officer of Health All Reference Number: SUMMARY The Human
More informationTuberculosis in Canada - Summary 2015
Tuberculosis in Canada - Summary 2015 V Gallant 1, V Duvvuri 1, M McGuire 1 Abstract Background: Tuberculosis (TB) is a global health problem that affects an estimated 10 million people each year. In Canada,
More informationPoison Control Centres
Poison Control Centres Monica Durigon Field Epidemiologist Public Health Agency of Canada Joanne Stares Public Health Officer Public Health Agency of Canada Placement site: BC Centre for Disease Control
More informationOrganized Breast Cancer Screening Programs in Canada REPORT ON PROGRAM PERFORMANCE IN 2007 AND 2008
Organized Breast Cancer Screening Programs in Canada REPORT ON PROGRAM PERFORMANCE IN 2007 AND 2008 Organized Breast Cancer Screening Programs in Canada REPORT ON PROGRAM PERFORMANCE IN 2007 AND 2008 TO
More informationThe 2012 SAGE Wait Time Program: Survey of Access to GastroEnterology in Canada Can J Gastroenterol 2013;27:83-9.
The 2012 SAGE Wait Time Program: Survey of Access to GastroEnterology in Canada Can J Gastroenterol 2013;27:83-9. Desmond Leddin MB, David Armstrong MD, Mark Borgaonkar MD, Ronald J Bridges MD, Carlo A
More informationWEST NILE VIRUS AND OTHER MOSQUITO-BORNE DISEASE NATIONAL SURVEILLANCE REPORT
WEST NILE VIRUS AND OTHER MOSQUITO-BORNE DISEASE NATIONAL SURVEILLANCE REPORT AUG 3 TO SEPT 5, 215 REPORT WEEK 35 CANADA HUMANS During surveillance week 35, ending on Sept 5, 215, three (3 ) human clinical
More informationThe HIV testing process
FACTSHEET The HIV testing process Summary There are a few steps that a person will take in the HIV testing process. To access an HIV test, people can request a test or may be offered a test. There are
More informationWEST NILE VIRUS AND OTHER MOSQUITO-BORNE DISEASE NATIONAL SURVEILLANCE REPORT
WEST NILE VIRUS AND OTHER MOSQUITO-BORNE DISEASE NATIONAL SURVEILLANCE REPORT NOV 1 TO NOV 7, 215 REPORT WEEK 44 CANADA HUMANS During surveillance week 44, ending on Nov 7, 215, one (1) human clinical
More informationCanada s Inter agency Wild Bird Influenza Survey. Draft Proposal for the Survey Version 1 25 January 2010
Canada s Inter agency Wild Bird Influenza Survey Draft Proposal for the 2010 11 Survey Version 1 25 January 2010 Introduction Canada s wild bird influenza survey has been carried out each year since 2005.
More informationThe 2014 Cancer System Performance Report
The 2014 Cancer System Performance Report MARCH 2014 This document has been made possible through a financial contribution from Health Canada, through the Canadian Partnership Against Cancer. The views
More informationCORD Rare Disease Patient Survey
CORD Rare Disease Patient Survey 7 March 2015 Powered by 491 Eng + 61 Fr = 552 Total Responses March 3, 2015 Q1: Who is answering this questionnaire? 534 Responses 3 Q3: What is gender of person with rare
More informationAppendix A: Introduction to Imaging Modalities for Which Data Were Collected in the 2017 Imaging Inventory
Appendix A: Introduction to Imaging Modalities for Which Data Were Collected in the 207 Imaging Inventory Computed Tomography Computed tomography (CT) employs X-rays as a source of ionizing radiation,
More informationThe epidemiology of HIV in Canada
FACTSHEET The epidemiology of HIV in Canada This fact sheet provides a snapshot of the HIV epidemic in Canada. It is one of a series of fact sheets on the epidemiology of HIV and hepatitis C in Canada.
More informationWEST NILE VIRUS AND OTHER MOSQUITO-BORNE DISEASE NATIONAL SURVEILLANCE REPORT
WEST NILE VIRUS AND OTHER MOSQUITO-BORNE DISEASE NATIONAL SURVEILLANCE REPORT OCT 4 TO OCT 1, 215 REPORT WEEK 4 CANADA HUMANS During surveillance week 4, ending on Oct.1, 215, six (6) human clinical cases
More informationImpaired driving statistics
driving statistics Telling Canada s story in numbers Yvan Clermont Canadian Centre for Justice Statistics Standing Senate Committee on Legal and Constitutional Affairs February 8 th, 2018 Key points While
More informationWest Nile virus and Other Mosquito-borne Diseases National Surveillance Report August 6 to August 12, 2017 (Week 32)
West Nile Virus West Nile virus and Other Mosquito-borne Diseases National Surveillance Report August 6 to August 12, 217 (Week 32) Canada Humans During week 32, August 6 to August 12, 217, the province
More informationPROFILE AND PROJECTION OF DRUG OFFENCES IN CANADA. By Kwing Hung, Ph.D. Nathalie L. Quann, M.A.
PROFILE AND PROJECTION OF DRUG OFFENCES IN CANADA By Kwing Hung, Ph.D. Nathalie L. Quann, M.A. Research and Statistics Division Department of Justice Canada February 2000 Highlights From 1977 to 1998,
More informationHealth Canada s Strategy Against Tuberculosis for First Nations On-Reserve
Health Canada s Strategy Against Tuberculosis for First Nations On-Reserve Health Canada is the federal department responsible for helping the people of Canada maintain and improve their health. We assess
More informationCharacterization and proposed nomenclature of epidemic strains of MRSA in Canada
ORIGINAL ARTICLE Characterization and proposed nomenclature of epidemic strains of MRSA in Canada AE Simor MD FRCPC 1,3, D Boyd MSc 4, L Louie ART 1, A McGeer MD FRCPC 2,3, M Mulvey PhD 4, BM Willey ART
More informationMAJOR RELEASES OTHER RELEASES PUBLICATIONS RELEASED 5
Catalogue 11-001E (Français 11-001F) ISSN 0827-0465 Monday, July 27, 1998 For release at 8:30 a.m. MAJOR RELEASES Cancer incidence and mortality, 1991 to 1993 2 The incidence of new cancer cases as well
More information11 to 17 May, 2014 (Week 20)
Hanks you Overall Summary 11 to 17 May, 2014 (Week 20) In week 20, influenza activity in Canada continued to decline, although some regions reported small increases in circulation of influenza B. Late-season
More informationRespiratory Virus Detections in Canada Respiratory Virus Report, Week 10 - ending March 9, 2019
Respiratory Virus Detections in Canada Respiratory Virus Report, Week 1 - ending March 9, 19 The Respiratory Virus Detection Surveillance System collects data from select laboratories across Canada on
More informationCanadian Organ Replacement Register Annual Report. Treatment of End-Stage Organ Failure in Canada, 2000 to 2009
Canadian Organ Replacement Register Annual Report Treatment of End-Stage Organ Failure in Canada, 2000 to 2009 January 2011 Who We Are Established in 1994, CIHI is an independent, not-for-profit corporation
More information2017 JOB MARKET & EMPLOYMENT SURVEY EXECUTIVE SUMMARY
2017 JOB MARKET & EMPLOYMENT SURVEY EXECUTIVE SUMMARY Pay & Employment Rates The Canadian Dental Hygienists Association (CDHA) retained Framework Partners Inc. to conduct the 2017 Job Market and Employment
More informationCADTH Optimal Use Report
Canadian Agency for Drugs and Technologies in Health Agence canadienne des médicaments et des technologies de la santé CADTH Optimal Use Report Pilot Project Guidance on 1.5 Tesla Magnetic Resonance Imaging
More informationPhysical Medicine & Rehabilitation. Physical Medicine and Rehabilitation Profile
Physical Medicine & Rehabilitation Updated March 2018 Click on any of the contents below to navigate to the slide. Please click the home icon located at the top right of each slide to return to the table
More informationWaiting Your Turn Wait Times for Health Care in Canada, 2017 Report
2017 Fraser Institute Waiting Your Turn Wait Times for Health Care in Canada, 2017 Report by Bacchus Barua Barua Waiting Your Turn: 2017 Report i Contents Executive summary / iii Findings / 1 Method /
More informationCorneal transplant (CT) surgery remains the most common
Efficacy of Routine Notification and Request on reducing corneal transplantation wait times in Canada Mahta Rasouli,* MD; Valerie B. Caraiscos, MD, PhD; Allan R. Slomovic, MA, MD, FRCSC ABSTRACT RÉSUMÉ
More informationTreatment of End-Stage Organ Failure in Canada
Treatment of End-Stage Organ Failure in Canada 2002 and 2003 C a n a d i a n O r g a n R e p l a c e m e n t R e g i s t e r Contents of this publication may be reproduced in whole or in part, provided
More informationLIST OF FIGURES INTRODUCTION
SUPPLEMENT: 2017 INTRODUCTION This document is a supplement to the PMPRB publication Market Intelligence Report: Biologic Response Modifier Agents, 2015 1 produced under the NPDUIS initiative. The supplement
More informationWaiting Your Turn. Wait Times for Health Care in Canada, 2018 Report. by Bacchus Barua and David Jacques. with Antonia Collyer
Waiting Your Turn Wait Times for Health Care in Canada, 2018 Report by Bacchus Barua and David Jacques with Antonia Collyer 2018 Fraser Institute Waiting Your Turn Wait Times for Health Care in Canada,
More informationNational Surveillance of Antimicrobial Susceptibilities of Neisseria gonorrhoeae
National Surveillance of Antimicrobial Susceptibilities of Neisseria gonorrhoeae Annual Summary 2011 Streptococcus and STI Unit Bacteriology and Enteric Diseases Program National Microbiology Laboratory
More informationSevere Acute Respiratory Syndrome (SARS) Lessons Learned
GLOBAL HEALTH RISK FRAMEWORK: A WORKSHOP ON RESILIENT AND SUSTAINABLE HEALTH SYSTEMS TO RESPOND TO GLOBAL INFECTIOUS DISEASE OUTBREAKS Severe Acute Respiratory Syndrome (SARS) Lessons Learned Rob Fowler,
More informationNeurology. Neurology Profile
Updated March 2018 Click on any of the contents below to navigate to the slide. Please click the home icon located at the top right of each slide to return to the table of contents slide. Neurology Slide
More informationMembership Application
Family Mediation Canada / Médiation Familiale Canada Membership Application Family Mediation Canada is an interdisciplinary association of professionals, working together, creating a better way to provide
More information